Every readout in the tiered biomarker list, mapped to what it would enable — by hardware tier, clinical or industrial setting, and how strong the published evidence is. Start with the full map, or open a focused read on CGT & CAR-T, oncology, or sepsis triage — each split into what is possible and what is not. Tier 1 is the label-free layer (the cartridge lyses with saponin and a stop reagent; no antibodies or dyes); Tier 2 is predicted virtual staining; Tier 3 is the reagent-based roadmap. No chip has been made and no design is verified: every Tier-1 number is simulation-level, and nothing here is on sale. The Tier-1 readouts supportable today are a white-cell count and a blast / abnormal-cell flag; the 3-part differential is the target. Red cells and platelets are lysed before the optics, so every red-cell and platelet readout is blocked until an unlysed side channel is designed — none is.
A cytometer measures cells — their size, structure and (at Tier 3) surface markers. It does not measure soluble chemistry, nucleic acids or tissue, and this cartridge lyses red cells and platelets before the optics. These are the hard edges around every claim above.